Huntington's Disease

References

Almqvist E, Adam S, Bloch M, et al. Risk reversals in predictive testing for Huntington disease. Am J Hum Genet. 1997;61:945-952.

Aoba S, Komiyama A, Yamada H, Hasegawa O. Action myoclonus in adult Huntington's disease. Rinsho Shinkeigaku. 1992;32:739-742.

Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors. 1999;9:261-266.

Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci. 1991;11:1649-1659.

Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther. 1999;10:2987-2997.

Brinkman, R. R.; Mezei, M. M.; Theilmann, J.; Almqvist, E.; Hayden, M. R. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997;60:1202-1210.

Brooks DJ. Functional imaging of movement disorders. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford, England: Butterworth-Heinemann Ltd.; 1996:79-81.

Castellanos-Ortega MR, Cruz-Aguado R, Martinez-Marti L. Nerve growth factor: possibilities and limitations of its clinical application. Rev Neurol. 1999;29:439-447.

Centonze D, Calabresi P, Pisani A, Marinelli S, Marfia GA, Bernardi G. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology. 1998;37:1063-1070.

Chen N, Luo T, Wellington C, et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem. 1999;72:1890-1898.

Davies SW, Turmaine M, Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90:537-548.

DiFiglia M, Sapp E, Chase KO, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1993;277:1990-1993.

Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81:163-221.

Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp Neurol. 1993;119:46-71.

Garside S, Furtado JC, Mazurek MF. Dopamine-glutamate interactions in the striatum: behaviourally relevant modification of excitotoxicity by dopamine receptor-mediated mechanisms. NeuroScience. 1996;75:1065-1074.

Gellera C, Meoni C, Castellotti B, et al. Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene [letter]. Am J Hum Genet. 1996;59:475-477.

Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia. 1989;4:282-287.

Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genet. 1996;13:442-449.

Harding AE. Movement disorders: genetic aspects. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford, England: Butterworth-Heinemann Ltd.; 1996:51-57.

Hughes PE, Alexi T, Williams CE, Clark RG, Gluckman PD. Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease. NeuroScience. 1999;92:197-209.

Huntington's disease and other choreas. In: Fahn S, Greene PE, Ford B, Bressman SB, eds. Handbook of Movement Disorders. Philadelphia, PA: Current Medicine, Inc.; 1998:75-95.

Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-983.

Hurlbert MS, Gianani RI, Hutt C, Freed CR, Kaddis FG. Neural transplantation of hNT neurons for Huntington's disease. Cell Transplant. 1999;8:143-151.

Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48:358-362.

Klawans HL. Chorea. Can J Neurol Sci. 1987;14:536-540.

Kordower JH, Isacson O, Emerich DF. Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible? Exp Neurol. 1999;159:4-20.

Krystal JH, D'Souza DC, Petrakis IL, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999;7:125-143.

Levine MS, Klapstein GJ, Koppel A, et al. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res. 1999;58:515-532.

Li XJ, Li SH, Sharp AH, et al. A huntingtin-associated protein enriched in brain and implications for pathology. Nature. 1995;378:398-402.

Lunkes A, Trottier Y, Mandel JL. Pathological mechanisms in Huntington's disease and other polyglutamine expansion diseases. Essays Biochem. 1998;33:149-163.

MacDonald ME, Novelletto A, Lin C, et al. The Huntington's disease candidate region exhibits many different haplotypes. Nature Genet. 1992;1:99-103.

Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol. 1992;15:63-68.

Nakao N, Grasbon-Frodl EM, Widner H, Brundin P. Antioxidant treatment protects striatal neurons against excitotoxic insults. NeuroScience. 1996;73:185-200.

Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 1999;399:263-267.

Online Mendelian Inheritance in Man (OMIM)™. National Center for Biotechnology Information Web site. John Hopkins University; McKusick VA, ed. 143100: Huntington disease; HD. Available at: http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?143100. Accessed February 2, 2000.

Panagopoulos I, Lassen C, Kristoffersson U, Aman P. A novel PCR-based approach for the detection of the Huntington disease associated trinucleotide repeat expansion. Hum Mutat. 1999;13:232-236.

Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data. Neuropharmacology. 1999;38:735-767.

Perez-Navarro E, Alberch J, Neveu I, Arenas E. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. NeuroScience. 1999;91:1257-1264.

Perez-Navarro E, Arenas E, Marco S, Alberch J. Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur J Neurosci. 1999;11:241-249.

Pundt LL, Narang N, Kondoh T, Low WC. Localization of dopamine receptors and associated mRNA in transplants of human fetal striatal tissue in rodents with experimental Huntington's disease. Neurosci Res. 1997;27:305-315.

Quinn N, Schrag A. Huntington's disease and other choreas. J Neurol. 1998;245:709-716.

Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry. 1998;65:577-579.

Ranen NG, Stine OC, Abbott MH, et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet. 1995;57:593-602.

Read AP. Huntington's disease: testing the test. Nature Genet. 1993;4:329-330.

Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as parkinson plus syndrome. J Neurol Neurosurg Psychiatry. 2000;68:238-241.

Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord. 1999;14:326-330.

Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55-66.

Simpson SA, Johnston AW. The prevalence and patterns of care of Huntington's chorea in Grampian. Brit J Psychiat. 1989;155:799-804.

Thompson PD, Bhatia KP, Brown P, et al. Cortical myoclonus in Huntington's disease. Mov Disord. 1994;9:633-641.

Topper R, Schwarz M, Lange HW, Hefter H, Noth J. Neurophysiological abnormalities in the Westphal variant of Huntington's disease. Mov Disord. 1998; 13:920-928.

van Dijk JG, van der Velde EA, Roos RAC, Bruyn GW. Juvenile Huntington disease. Hum Genet. 1986;73:235-239.

Doty RL. Olfactory deficit in Alzheimer's disease? Am J Psychiatry. 2001;158:1533-1534; discussion 1534-1535.

Gambardella A, Muglia M, Labate A, et al. Juvenile Huntington's disease presenting as progressive myoclonic epilepsy. Neurology. 2001;57:708-711.

Paulsen JS, Zhao H, Stout JC, et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 200128;57:658-662.

Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem. 2001;78:694-703.

Hashimoto T, Shindo M, Yanagisawa N. Enhanced associated movements in the contralateral limbs elicited by brisk voluntary contraction in choreic disorders. Clin Neurophysiol. 2001;112:1612-1617.

Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71:310-314.

Backman L, Farde L. Dopamine and cognitive functioning: brain imaging findings in Huntington'sdisease and normal aging [Review]. Scand J Psychol. 2001;42:287-296.

Suzuki M, Desmond TJ, Albin RL, Frey KA. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse. 2001;41:329-336.

Ishiguro H, Yamada K, Sawada H, et al. Age-dependent and tissue-specific CAG repeat instability occurs in mouse knock-in for a mutant Huntington's disease gene. J Neurosci Res. 2001;65:289-297.

Chaudhuri KR. Autonomic dysfunction in movement disorders [Review]. Curr Opin Neurol. 2001;14:505-511.

Chen S, Berthelier V, Yang W, Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol. 2001;311:173-182.

Trottier Y, Mandel JL. Biomedicine. Huntingtin--profit and loss. Science. 2001;293:445-446.

Rega S, Stiewe T, Chang DI, et al. Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor. Mol Cell Neurosci. 2001;18:68-79.

Modugno N, Curra A, Giovannelli M, et al. The prolonged cortical silent period in patients with Huntington's disease. Clin Neurophysiol. 2001;112:1470-1474.

Rosenblatt A, Brinkman RR, Liang KY, et al. Familial influence on age of onset among siblings with Huntington disease. Am J Med Genet. 2001;105:399-403.

Perutz MF, Windle AH. Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature. 2001;412:143-4.

Lamberg L. Psychiatric symptoms common in neurological disorders. JAMA. 2001;286:154-156.

Berrios GE, Wagle AC, Markova IS, et al. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers. Psychiatry Res. 2001;102:217-225.